Ongoing efforts are underway to develop SOD1 inhibitors for the treatment of cancer and ALS (Abati et al., 2020; Huang et al., 2000), and it is conceivable these may be useful in the context of PPM1D mutation. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.